Analyzing the Early CT findings and Clinical Features of 12 Patients with 2019 Novel Coronavirus Disease (COVID-19) in China

Xianwu Xia¹, Liang Sheng¹, Tiejun Yang¹, Guobing Zhang¹, Li Ding¹, Jianmin Shen¹,² and Jihong Feng²

¹Department of Radiology, Municipal Hospital Affiliated to Medical School of Taizhou University, Zhejiang, Taizhou, China
²Department of Oncology, Municipal Hospital Affiliated to Medical School of Taizhou University, Zhejiang, Taizhou, China

Corresponding author: Department of Radiology, Municipal Hospital Affiliated to Medical School of Taizhou University, 381-1 Middle Zhongshan Rd., Jiaojiang District, Taizhou, Zhejiang Province, 318000, China. Tel: +86-15157689870, Email: jh_f@163.com

Corresponding author: Department of Oncology, Municipal Hospital Affiliated to Medical School of Taizhou University, China 381-1 Middle Zhongshan Rd., Jiaojiang District, Taizhou, Zhejiang Province, 318000, China. Tel: +86-057689870, Email: sjm_60@126.com

Received 2020 April 06; Revised 2020 April 15; Accepted 2020 April 22.

1. Background

The initial cluster of severe pneumonia cases that triggered the COVID-19 epidemic was identified in Wuhan, China, in December 2019 (1, 2). As of Mar 28, 2020, a considerable number of confirmed cases of novel coronavirus infection are reported in the world’s countries and regions, including 82,236 patients in China and 516,951 patients outside of China. Despite the extensive implementation of control measures, human-to-human transmission has driven the rapid spread of the virus throughout the world and result in the number of confirmed and suspected cases of COVID-19 has risen, in just the past few weeks, with extraordinary speed. The “2019 novel Coronavirus” (2019-nCoV) or SARS-CoV-2 formally named by the World Committee on Virus Classification. There has been evidence that SARS-CoV-2 is highly contagious, with an average incubation period of 5.2 days and a basic regeneration number (R0) of 3.77 at the initial stage of the epidemic (3). The SARS-CoV-2 is propagated primarily via close contact, and exhaled droplets, with the incubation period usually from 1 - 14 days, can cause the symptoms, including fever, dry cough, fatigue, dyspnea, and so on in the pathogenesis of different stages of patients with COVID-19. At present, although the diagnosis of COVID-19 still depends on nucleic acid detection (4), its sensitivity is low, and some cases found in the clinic need to be confirmed by multiplex nucleic acid testing (5). It is worth noting that these
patients who were later diagnosed had positive lesions in the early stage of the CT image. Although the CT characteristics of COVID-19 that have been reported in the literature (5-10), due to the lack of sufficient autopsy specimens and pathological comparison, the understanding of its early CT changes is still not comprehensive enough. Therefore, early identification of COVID-19 is very important to control the epidemic and spread of the disease.

2. Objectives

In order to further improve the understanding of the CT features of COVID-19, the clinical features and imaging findings of 12 cases of early novel coronavirus pneumonia diagnosed in our hospital were retrospectively analyzed. The purpose of this study was to assess the performance of the early chest CT in the diagnosis of patients with COVID-19 from viral pneumonia.

3. Methods

3.1. Patient Population

The Ethics Committee of the Municipal Hospital Affiliated to Medical School of Taizhou University waived the need for informed consent for this study. This study consisted of 12 patients with COVID-19 pneumonia who met the inclusion criteria. We retrospectively analyzed 12 patients confirmed infected by the novel coronavirus from Jan 20 to Feb 23, 2020. Laboratory findings of COVID-19 were confirmed in the first admission hospital and verified by the Taizhou Center for Disease Control and Prevention (CDC). The patients with COVID-19 were confirmed to be infected by a real-time polymerase chain reaction (RT-PCR). The COVID-19 respiratory samples were tested using novel coronavirus ORF1ab/N gene nucleic acid detection kit (batch number: P732200130, manufacturer: Suzhou Tianlong Biotechnology Co., Ltd.). Two of the trained researchers recorded clinical data, including date of onset of symptoms, laboratory examinations, and other information. The general data and clinical features included age, sex, history of epidemiological exposure, clinical symptoms, blood routine (five classifications), hypersensitive C-reactive protein, and history (Table 1).

3.2. CT Scanning Protocol

The American GE Optima 540 16-layer spiral CT scanner was used. The patients were scanned with supine position, advanced head, and breath-holding after inspiration. The scanning range was from the tip of the lung to the bottom of the lung. The scanning parameters were as follows: tube voltage 120 kV, tube current 300 mA, pitch 1.75 mm, matrix 512 × 512, slice thickness 5 mm, visual field 350 mm × 350 mm, axial reconstruction Bone Plus, slice thickness 1.250 mm. The CV of Ct value was less than 5%, and the detection limit was 500 copies/mL.

3.3. CT Viewing and Evaluation

All CT images were analyzed by two trained chest radiologists with 10 - 15 years of experience, in a consistent manner. In case of disagreement, it is meticulously examined and reached a decision in consensus by the chief physician of the cardiothoracic group.

Image analysis, focused on the lesion features of each patient, included location, distribution, size, shape, number, density, internal structure, margin, degree of lung involvement, remaining lung manifestations and extrapulmonary manifestations (e.g., lymph node enlargement of mediastinal and/or bilateral hilar, pleural effusion). The description standards of CT performance parameters are as follows: (1) The location of lesion: the periphery, the center, the periphery, and the center are affected at the same time; the anterior and the posterior were involved at the same time (on the transverse CT image, draw a horizontal line across the midline of the axilla, divided into the anterior part and the posterior part. The outer third of the lung is defined as the peripheral type, and the rest is identified as the central type). (2) Lesion distribution: single lung lobe, multiple lung lobes, double lung lobe, and lung lobe are divided into the left lung (upper lobe, lower lobe) and right lung (upper lobe, middle lobe, lower lobe). (3) Lesion size: the length of the largest lesion was < 1 cm, 1 - 3 cm, > 3 cm. (4) Lesion morphology: nodules, patches, pulmonary segments, lobes (nodules less than 3 cm in diameter). (5) The number of lesions: 1, 2, 3, and more were multiple. (6) Lesion density: ground-glass opacity (GGO), consolidation, mixed GGO and consolidation type (according to the standard of Fleischner Society (11): ground-glass opacity is a slightly high-density shadow with vascular shadow; consolidation is a high-density opaque shadow in the lung, covering blood vessels and trachea wall shadow; GGO and consolidation type has both ground-glass opacity and solid components). (7) Internal structure: cavity, reticular, interlobular septal thickening, bronchial air sign, calcification, and internal vascular changes. (8) Edge of lesion: clear and blurred. (9) There are potential lung diseases such as emphysema or fibrosis. (10) Enlargement of lymph nodes: yes or no (enlargement of lymph nodes was defined as short diameter of supraaxial lymph nodes > 1 cm). (11) Pleural effusion: yes or no. (12) CT’s method for evaluating the degree of pulmonary involvement (12): both lungs were divided into 20 segments, 10 in the right lung and 10 in the left lung (Two segments in the posterior segment of the tip...
of the upper lobe of the left lung, two segments in the superi-
or and inferior lingual segment of the left lobe, and two
segments in the anterior basal segment of the lower lobe
of the left lung). If more than half of the lung segment with
the largest lesion area on the axial thin slice CT is involved,
the lung segment is recorded as one point, and if the lung
segment is involved and the part is not more than half, it is
recorded as 0.5 point. The scores were mild: 0 - 6, medium:
7: 12, heavy: > 12.

4. Results

4.1. Clinical Characteristics

A total of 12 patients with COVID-19 pneumonia were
entered into the study, including five males (41.7%) and
seven females (58.5%), aged from 19 to 80 years old, with
an average of 38 years old. The general data, main clin-
ical symptoms of 12 patients with COVID-19 are shown in
Table 1. In 9 cases with definite contact history and con-
tact time, the median incubation period was eight days
(2 - 22 days). The contact time cannot be determined in 3
cases. There was no clinical symptom in one case (fever oc-
curred 2 days later). There were 11 cases with clinical
symptoms, nine cases with fever (75.0%), eight cases with cough
(66.7%), three cases with fatigue (25.0%), and 1 case with
other symptoms such as expectoration, sore throat, chest
tightness, abdominal pain, diarrhea, nausea and vomiting
(8.3%). The laboratory findings of 12 patients with COVID-19
are shown in Table 2. Routine blood tests were performed
for 12 patients. Laboratory results showed that white blood
cells were normal in 10 cases (83.3%), increased in one case
(8.3%), slightly decreased in one case (8.3%), neutrophil per-
centage was normal in 11 cases (91.7%), lymphocyte percentage
decreased in four cases (33.3%), the absolute number

Table 1. General Data and Clinical Features of 12 Newly Treated Patients with COVID-19 Pneumonia

<table>
<thead>
<tr>
<th>Characteristics</th>
<th>Case 1</th>
<th>Case 2</th>
<th>Case 3</th>
<th>Case 4</th>
<th>Case 5</th>
<th>Case 6</th>
<th>Case 7</th>
<th>Case 8</th>
<th>Case 9</th>
<th>Case 10</th>
<th>Case 11</th>
<th>Case 12</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age (y)</td>
<td>24</td>
<td>45</td>
<td>75</td>
<td>19</td>
<td>32</td>
<td>70</td>
<td>67</td>
<td>68</td>
<td>24</td>
<td>78</td>
<td>30</td>
<td>39</td>
</tr>
<tr>
<td>Incubation period (d)</td>
<td>5</td>
<td>6</td>
<td>2</td>
<td>8</td>
<td>Not clear</td>
<td>8</td>
<td>Not clear</td>
<td>4</td>
<td>11</td>
<td>11</td>
<td>22</td>
<td></td>
</tr>
<tr>
<td>Gender</td>
<td>Female</td>
<td>Female</td>
<td>Male</td>
<td>Female</td>
<td>Male</td>
<td>Female</td>
<td>Female</td>
<td>Male</td>
<td>Female</td>
<td>Male</td>
<td>Female</td>
<td>Female</td>
</tr>
<tr>
<td>Symptom time (d)</td>
<td>3</td>
<td>4</td>
<td>1</td>
<td>3</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>3</td>
<td>1</td>
<td>2</td>
<td>4</td>
<td></td>
</tr>
<tr>
<td>Temperature [°C]</td>
<td>Normal</td>
<td>38.3</td>
<td>38.4</td>
<td>37.9</td>
<td>38.2</td>
<td>37.7</td>
<td>39.5</td>
<td>37.5</td>
<td>38.4</td>
<td>37.9</td>
<td>Normal</td>
<td>37.5</td>
</tr>
<tr>
<td>Cough</td>
<td>None</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
</tr>
<tr>
<td>Expectoration</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td>Sore throat</td>
<td>None</td>
<td>None</td>
<td>Yes</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td>Nausea, vomiting</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td>Diarrhea</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td>Fatigue</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td>OD</td>
<td>None</td>
<td>None</td>
<td>PPA</td>
<td>None</td>
<td>AIDS</td>
<td>None</td>
<td>None</td>
<td>BP</td>
<td>None</td>
<td>BP</td>
<td>BP</td>
<td>PT</td>
</tr>
</tbody>
</table>

Abbreviations: AIDS, acquired immune deficiency syndrome; HBP, high blood pressure; OD, other diseases; PPA, postoperative pituitary adenoma; PT, postoperative teratoma.

4.2. CT Findings of COVID-19 Pneumonia

The early features of chest CT of 11 patients with COVID-
19 pneumonia are shown in Table 3. Among the 12 patients
with COVID-19, 11 patients underwent chest CT within 1 -
4 days after the onset of clinical symptoms, and only one
asymptomatic patient, which have been received chest CT
scanning, developed a fever 2 days later. Chest X-ray was
performed in 3 of 12 patients with COVID-19, and the ex-
amination showed that there were negative in all 3 cases.
Among the 12 cases, 1 case had a normal chest CT (GGO ap-
ppeared in both lungs of CT 2 days later). The early CT fea-
tures of 11 patients with COVID-19 are shown in Table 2. In
the early stage, the shape of chest CT could be nodular (1,
9.1%) (Figure 1), patchy (10, 90.9%) (Figure 2), mainly sub-
pleural and posterior of the periphery of the lung (8, 72.7%)
(Figure 3), and involving both lungs more frequently (7,
63.6%). The density is mainly mixed ground-glass opacity
(8, 72.7%) (Figure 2), followed by pure ground-glass opacity
(2, 18.2%) (Figure 4) and solid shadow (1, 9.1%) (Figure
4). Most of the inner density was uneven, manifested as “crazy-paving pattern” (8, 72.7%), with grid changes (7,
63.6%) (Figure 2), interlobular septal thickening (8, 72.7%)
and air bronchial sign (7, 63.6%) (Figure 5). Bronchovas-
cular bundle thickening (8, 72.7%) (Figure 2) and fibrosis (8,
72.7%) (Figure 4). Segmental atelectasis occurred in 1 case
(9.1%) (Figure 2). 1 case (9.1%) had a small amount of pleural

effusion. There were no cavities, calcification, enlargement of mediastinal, and hilar lymph nodes.

5. Discussion

At present, the epidemic of COVID-19 is currently affecting multiple countries and may cause feelings of fear and helplessness. Once the medical resources run out, the mortality rate will increase rapidly. At present, confirmed cases in European and American countries present a comprehensive outbreak of the situation, the World Health Organization (WHO) has characterized coronavirus as a global pandemic, calling on each country to take urgent and active action. However, there is no specific drug treatment or vaccine for COVID-19 pneumonia. In light of the urgent clinical demand, early detection, early isolation, and early treatment are very necessary. According to the latest guidelines for diagnosis and treatment issued by the Chinese government (4), the diagnosis of COVID-19 pneumonia could be confirmed by RT-PCR or gene sequencing. However, this detection method lacks sufficient sensitivity, good stability, and relatively long processing time is conducive to the control of the disease epidemic. It is reported (13) that the total RT-PCR positive rate of pharyngeal swab samples is about 30% to 60%. In addition, there are several defects in RT-PCR detection, such as limited sample collection and transportation, inconsistent performance of the kit, and so on. In the current emergency, the low sensitivity of RT-PCR means that a certain amount of patients with COVID-19 may not be confirmed and, therefore, unable to isolate and receive appropriate treatment in a timely manner. Because of the highly contagious nature of the virus, these patients pose a high risk of infecting more people. Reports also showed that chest CT presents pulmonary abnormalities in patients with COVID-19 with clinical symptoms and negative RT-PCR results (14, 15). AI et al. (16) compared chest CT results of 1,014 patients with suspected COVID-19 with the initial and series of RT-PCR results and found that chest CT is more sensitive than RT-PCR in the diagnosis of COVID-19. Therefore, in the current outbreak phase, chest CT imaging may be a more practical and rapid method to diagnose and evaluate COVID-19. Novel coronavirus (SARS-CoV-2) is highly contagious and easy to spread from person to person (1, 3). COVID-19

![Figure 1](image-url)

**Figure 1.** Female, 24 years old, come from Wuhan city, without clinical symptoms (have a fever after 2 days). No obvious abnormality was found in chest X-ray (A). Solid nodule of the left lower lobe with halo sign in chest CT (B), (window level-600, window width-1600).
Xia X et al.

Figure 2. Male, 75 years old, contacted with patients with COVID-19 six days ago and had a fever for four days. Chest CT showed patchy mixed GGO, scattered under the pleura and presented interlobular septal thickening (black arrow) (A), bronchiectasis (white arrow) (B) in transverse images, and in sagittal position (C), vascular thickening and segmental atelectasis (red arrow) in coronal images (D). (CT image window level-600, window width-1600).

is common in adults and rare in children (17). In this study, 12 patients with COVID-19 pneumonia are all adults with a history of epidemiological contact, so it is very important to inquire about the history of epidemiology in fever clinics of medical institutions outside the epidemic area. Li et al. (3) found that the incubation period of COVID-19 was 5.5 d (4.1 - 7.0 d). This study found that the median incubation period was 8 d (2 - 22 d). Therefore, epidemic contacts need to be observed in isolation for 14 days (4). At present, it is reported in the literature (1, 10) that the vast majority of patients with COVID-19 have respiratory symptoms such as fever, cough, diarrhea, and vomiting are rare. In this study, the symptoms of 12 patients with COVID-19 at the onset of illness were fever (81.8%) and cough (54.5%), a few fatigue occurred in 3 cases (25.0%), and some patients had symptoms such as expectoration, pharyngalgia, chest tightness, abdominal pain, diarrhea, nausea and vomiting (1 case, 8.3% each), which was consistent with the literature report. Laboratory examination showed that most of the white blood cells were normal (81.8%), the absolute number of lymphocytes decreased slightly (54.5%), and hypersensitive C-reactive protein could be increased (45.5%). These clinical features are similar to those of SARS-CoV and MERS-CoV infection (10, 18, 19). For the patients with epidemiological history and these clinical features, we should be vigilant and carry out chest CT examination and nucleic acid detection in time.

Chest X-ray in patients with early COVID-19 may be negative or show only a little patchy increased density (20). In this study, it was found that the chest X-ray examination of 3 patients was negative, and the lesions were found by further examination of CT. It is suggested that an ordinary chest X-ray may lead to the omission of early lesions. Therefore, chest CT screening is recommended for patients with fever, especially those with a history of epidemiology.

The main features of pulmonary CT in patients with
Figure 3. Male, 70 years old, contacted with patients with COVID-19 nine days ago and had a fever for one day. Patchy ground-glass opacity was scattered under the pleura of both lungs, showing fireworks-like changes, and vascular shadows were seen in transverse images (A and B) or sagittal position (C) or coronal images (D). (window level 600, window width 1600).

eyearly COVID-19 were nodular and patchy consolidation shadow, pure ground-glass opacity and mixed ground-glass opacity, most of which were multiple lesions, which were usually distributed around the bronchovascular bundles of both lungs and/or under the pleura (6, 8, 21-25). In this study, 11 cases of early COVID-19 pneumonia showed patchy mixed ground-glass opacity at the periphery and posterior part of the lung on CT. Most of the inner density was uneven, manifested as “crazy-paving pattern” (72.7%), with grid changes (63.6%), interlobular septal thickening (72.7%), and air bronchial sign (63.6%), bronchovascular bundle thickening (72.7%), and fibrosis (72.7%). Yan et al. (26) found that the S protein of coronavirus binds to human ACE2 to replicate, and the ACE2 receptor mainly exists in alveolar epithelial cells. Hence, the CT imaging findings of patients with COVID-19 are mainly alveolar exudation ground-glass opacity. Tian et al. (27) reported that the early pathological changes of SARS-CoV-2 pneumonia found in two cases of lung tumor resection were interstitial lymphocyte infiltration, alveolar type II epithelial injury, pulmonary edema, and non-protruding hyaline membrane. On the other hand, Xu et al. (28) postmortem pathology showed diffuse alveolar injury, formation of transparent membrane, exfoliation of the alveolar epithelium, exudation of the alveolar cavity and scattered monocytes, dilatation of small blood vessels, and transparent membrane, which may be the pathological basis of the white lung on CT in advanced patients. These two studies found pathological changes at different stages of COVID-19 pneumonia. Referring to the previous SARS pneumonia report (29), we believe that ground-glass opacity may be caused by alveolar wall injury and alveolar serous inflammatory exuda-
Figure 4. Female, 67 years old, came from Wuhan city, close contact time is not clear, have a fever for one day. There is a patchy ground-glass shadow in the upper lobe of the left lung, showing an anti-halo sign (A). The lesion showed consolidation of the lung (B). Subpleural mixed ground-glass opacity, interlobular septum thickening, with “crazy-paving pattern” (C). Left lower lobe fibrous cord shadow (red arrow) (D). (all CT images window level-600 and window width-1600).

Figure 5. Female, 68 years old, come from Wuhan, close contact time is not clear, fever for one day. Both lungs scattered under the pleura mixed ground-glass opacity, interlobular septum thickening, with “crazy-paving pattern” (A and B). (window level-600 and window width-1600 in all CT images).

tion, followed by interstitial inflammation leading to interlobular septal thickening and “crazy-paving pattern,” and increased alveolar inflammatory exudation in the center of the lesion leads to consolidation. Tian et al. (27) believe that the pathological characteristics of COVID-19 are very similar to SARS and MERS coronavirus infection. According to the similarity between SARS-CoV-2 virus and SARS coronavirus as high as 85%, we speculate that the CT performance of COVID-19 is similar to that of SARS.

A study by Pan et al. (7) showed that the initial chest
Table 3. Early Features of Chest CT of 12 Patients with COVID-19 Pneumonia

<table>
<thead>
<tr>
<th>Characteristics</th>
<th>All, No. (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Location</strong></td>
<td></td>
</tr>
<tr>
<td>BL</td>
<td>7 (63.6)</td>
</tr>
<tr>
<td>LLLL</td>
<td>1 (9.1)</td>
</tr>
<tr>
<td>LLRL</td>
<td>1 (9.1)</td>
</tr>
<tr>
<td>ULLLL</td>
<td>1 (9.1)</td>
</tr>
<tr>
<td>LLBL</td>
<td>1 (9.1)</td>
</tr>
<tr>
<td><strong>Distribution</strong></td>
<td></td>
</tr>
<tr>
<td>Rear periphery</td>
<td>8 (72.7)</td>
</tr>
<tr>
<td>Scattered</td>
<td>3 (27.3)</td>
</tr>
<tr>
<td><strong>Number</strong></td>
<td></td>
</tr>
<tr>
<td>Single</td>
<td>1 (9.1)</td>
</tr>
<tr>
<td>Two</td>
<td>2 (18.2)</td>
</tr>
<tr>
<td>Multiple</td>
<td>7 (63.6)</td>
</tr>
<tr>
<td><strong>Long diameter, cm</strong></td>
<td></td>
</tr>
<tr>
<td>&lt; 1</td>
<td>1 (9.1)</td>
</tr>
<tr>
<td>1 - 3</td>
<td>2 (18.2)</td>
</tr>
<tr>
<td>&gt; 3</td>
<td>8 (72.7)</td>
</tr>
<tr>
<td><strong>Shape</strong></td>
<td></td>
</tr>
<tr>
<td>Nodular</td>
<td>1 (9.1)</td>
</tr>
<tr>
<td>Patchy</td>
<td>10 (90.9)</td>
</tr>
<tr>
<td><strong>Density</strong></td>
<td></td>
</tr>
<tr>
<td>pGGO</td>
<td>2 (18.2)</td>
</tr>
<tr>
<td>Solid</td>
<td>1 (9.1)</td>
</tr>
<tr>
<td>mGGO</td>
<td>8 (72.7)</td>
</tr>
<tr>
<td><strong>Grid shape</strong></td>
<td></td>
</tr>
<tr>
<td>IST</td>
<td>8 (72.7)</td>
</tr>
<tr>
<td>ABS</td>
<td>7 (63.6)</td>
</tr>
<tr>
<td>BBT</td>
<td>8 (72.7)</td>
</tr>
<tr>
<td>Fibrosis</td>
<td>8 (72.7)</td>
</tr>
<tr>
<td><strong>Margin</strong></td>
<td></td>
</tr>
<tr>
<td>Well-defined</td>
<td>6 (54.5)</td>
</tr>
<tr>
<td>Ill-defined</td>
<td>5 (45.5)</td>
</tr>
<tr>
<td><strong>DLI</strong></td>
<td></td>
</tr>
<tr>
<td>Mild</td>
<td>10 (90.9)</td>
</tr>
<tr>
<td>Moderate</td>
<td>1 (9.1)</td>
</tr>
<tr>
<td>Severe</td>
<td>0</td>
</tr>
<tr>
<td>Atelectasis</td>
<td>1 (9.1)</td>
</tr>
<tr>
<td>Cavity</td>
<td>0</td>
</tr>
<tr>
<td>Calcification</td>
<td>0</td>
</tr>
<tr>
<td>Emphysema</td>
<td>0</td>
</tr>
<tr>
<td>ELN</td>
<td>0</td>
</tr>
<tr>
<td><strong>Pleural effusion</strong></td>
<td></td>
</tr>
<tr>
<td></td>
<td>1 (9.1)</td>
</tr>
</tbody>
</table>

Abbreviations: ABS, air bronchial sign; BBT, bronchovascular bundle thickening; BL, bilateral lungs; DLI, degree of lung involvement; ELN, enlarged lymph nodes; IST, interlobular septal thickening; LLRL, the lower lobe of bilateral lung; ULLLL, lower lobe of the left lung; LLBL, the lower lobe of right lung; mGGO, mixed ground-glass opacity; pGGO, pure ground-glass opacity; ULLLL, the upper and lower lobe of the left lung.

CT of patients with COVID-19 pneumonia revealed a small ground-glass opacity under the pleura, and then gradually became solid and enlarged, and a “crazy-paving pattern” appeared. Jiang et al. (23) also reported that 17 cases of subclinical CT were characterized by small ground-glass nodules or ground-glass opacity along the subpleural and/or bronchovascular bundles, without solid nodules. In this study, it was found that the early chest CT of one patient with COVID-19 showed left lower lobe nodule shadow with peripheral halo sign. Wu et al. (22) also reported a patient with a fever for two days. Multiple nodules with halo sign in both lungs were found on CT for the first time. Reexamination of CT on the 8th and 11th day showed that the nodule density decreased and gradually changed to ground-glass opacity. We believe that the early appearance of nodules with halo sign may be one of the earliest imaging findings in some patients with COVID-19 pneumonia. Yang et al. (30) study on the CT manifestations of 8 cluster cases of imported COVID-19 found that the chest CT images of these patients were various, but absorbed quickly, suggesting that the clinical symptoms and CT manifestations of overseas imported cases are more concealed and complex, so it is necessary to be vigilant and avoid misdiagnosis.

It has been reported in the literature (6, 23) that small ground-glass nodules or ground-glass shadow may appear in chest CT in patients with COVID-19 without clinical symptoms. In this study, an asymptomatic patient was found, and a nodular shadow of the left lower lobe was found on chest CT, which was consistent with the literature. Therefore, our study displays that lung manifestations can be earlier than clinical symptoms, and the chest CT plays an important role in early detection, timely prevention, and control in these patients with COVID-19.

A few COVID-19 patients with positive nucleic acid tests showed no obvious abnormality in early CT (6, 7, 9, 10). In this group, one patient with fever and other clinical symptoms had normal CT examination, and CT showed ground-glass opacity in both lungs 2 days later, which indicated that the lung manifestation could be later than the clinical symptoms. In two COVID-19 patients reported by Tian et al. (27), no abnormality was found in CT examination before the operation. Still, postoperative pathology showed edema, protein exudation, only a small amount of inflammatory cell infiltration, focal multinucleated giant cell formation, and ground-glass shadow in CT, which was similar to that in this case. On the basis of these considerations, we think that inflammatory reaction has been found in this part of COVID-19 patients, but chest CT has not been shown yet.

It is worth mentioning that there are two important limitations to the study. Firstly, due to the short course of the disease with COVID-19 pneumonia, continuous variations of chest CT during its entire course have not been completely followed and recorded for all patients. Much
more importantly, there is not adequate pathologic data on these patients for comparative research to be implemented.

In conclusion, the clinical characteristics of 2019-nCoV pneumonia are similar to those of common viral pneumonia. The chest CT findings of early COVID-19 showed characteristic features, with nodular shadow or ground-glass opacity along the subpleural or/and along with the bronchovascular bundle. The chest CT images may be helpful for the early detection of novel coronavirus pneumonia.

Footnotes

Authors’ Contribution: Study concept and design: Xianwu Xia, Liang Sheng, Jihong Feng; acquisition of data: Guobing Zhang, Li Ding; analysis and interpretation of data: Xianwu Xia, Liejun Yang; drafting of the manuscript: Xianwu Xia, Jihong Feng; critical revision of the manuscript for important intellectual content: Xianwu Xia, Jihong Feng, Jianmin Shen; statistical analysis: Xianwu Xia, Jihong Feng.

Conflict of Interests: The authors have no conflict of interest.

Ethical Approval: The Ethics Committee of the Municipal Hospital Affiliated to Medical School of Taizhou University waived the need for informed consent for this retrospective study.

Funding/Support: This work was supported by projects from the key disciplines of medicine in Taizhou (2019-2022), the National Natural Science Foundation of China (81560407) and Natural Science Foundation of Zhejiang Province (Y20H6021).

Informed Consent: Since this was a retrospective study and MRI images were obtained for diagnostic reasons before the beginning of the study and not for research purposes, informed consent was waived by the Institutional Ethics Committee. No harm (neither to the fetus nor to the mother) or extra charges was made to the subjects during the reviewing MR images.

References


